Table 2
Rates of cataract progression and intraocular pressure elevation (numbers are number of eyes (%) (n = 51 eyes))
| *Cataract progression was assessed by slit lamp biomicroscopy throughout the follow up period and was defined as new or increase in any type of lens opacification after triamcinolone infusion (arbitrary scale 1–4). | |
| †Intraocular pressure (IOP) elevation was defined as an IOP greater than 22 mm Hg by applanation tonometry. All eyes with IOP elevation were successfully treated with topical antiglaucoma medications, except for one eye in a patient with Behçet’s disease that eventually underwent filtration surgery. | |
| Cataract progression* | |
| Total | 16 (31) |
| Eyes receiving more than one triamcinolone infusion | 9 (18) |
| Eyes receiving concomitant corticosteroid eyedrops | 14 (27) |
| Eyes in patients receiving concomitant oral corticosteroids | 1 (2) |
| Eyes that underwent cataract surgery | 3 (6) |
| Intraocular pressure elevation† | |
| Total | 14 (27) |
| Eyes receiving more than one triamcinolone infusion | 6 (12) |
| Eyes receiving concomitant corticosteroid eyedrops | 11 (22) |
| Eyes in patients receiving concomitant oral corticosteroids | 3 (6) |
| Eyes that underwent filtration surgery | 1 (2) |
